Comparative Efficacy and Safety of Potassium-Competitive Acid Blocker- and Proton Pump Inhibitor-Based Bismuth Quadruple Therapy for <i>Helicobacter pylori</i> Eradication: A Network Meta-Analysis.

In the random-effects model ( Figure 2 ), the keverprazan-based treatment showed a trend toward higher eradication rates than the esomeprazole-based treatment (treatment effect (TE) = 0.06; 95% CI: −0.01–0.13; P = .0759), although the difference was not statistically significant.

also in 53,322 other papers

pylori infection was 9%, with an increasing trend after the first (4%), second (6%), third (8%), and fourth years or longer (12%).

also in 63,971 other papers